Bristol-Myers Squibb Slashes FY26 EPS Outlook, But Raises Revenue Forecast - Update

rttnews.com · 2026-10-29

While reporting financial results for the third quarter on Thursday, Bristol-Myers Squibb Co. (BMY) slashed its earnings guidance for the full-year 2026, while raising annual revenue outlook.

TickrTrends take: Bristol-Myers Squibb's decision to lower earnings per share guidance while raising revenue expectations suggests margin pressure ahead, which becomes particularly relevant given TickrTrends' overvalued assessment of the stock. A valuation-focused reader should monitor whether the company can demonstrate a path to profitability growth that justifies current pricing, as revenue increases alone may not offset the earnings headwinds the company is signaling. In the Healthcare sector where BMY competes, this divergence between top-line and bottom-line guidance warrants close attention to cost management and pipeline execution in coming quarters.

Read the full story at rttnews.com →